Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | CFD | P00746 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.50 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383357 | 0.88 | PARP1 (0.54) | KDM4EALDH1A1THRBHPGDF2 | |
| SCHEMBL5534473 | 0.81 | CREBBP (0.71) | KDM4EALDH1A1HPGDF2CFD | |
| SCHEMBL29771053 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1THRBHPGDSIRT2 | |
| SCHEMBL118684 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1THRBHPGDSIRT2 | |
| SCHEMBL10803052 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1HPGDF2CFD | |
| SCHEMBL30844878 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1THRBHPGDKIF11 | |
| SCHEMBL69604 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1THRBHPGDKIF11 | |
| SCHEMBL1668291 | 0.79 | F2 (0.56) | F2CFDMAOAMAOBACHE | |
| SCHEMBL19304158 | 0.78 | KDM4E (0.66) | KDM4EALDH1A1HPGDF2CFD | |
| Hydrochloric Acid SCHEMBL9746959 | 0.77 | KDM4E (0.65) | KDM4EALDH1A1THRBHPGDKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4514804-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | Viscient Bio, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119487031-A | Tryptanthrin derivatives and uses thereof | 威森特生物公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-2791121-B1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2791121-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8524745-B2 | Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2013090227-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150413-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-7803811-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | US | disclosed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | disclosed |
| CN-100413863-C | 1,2, 3-substituted indolizine derivatives, FGF inhibitors, process for preparing them and pharmaceutical compositions containing them | SANOFI AVENTIS (FR) | 2008-08-27 | — | — | CN | disclosed |
| WO-2007038571-A2 | PROLYL HYDROXYLASE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | disclosed |
| CN-1649867-A | Novel 1,2, 3-substituted indolizine derivatives, FGF inhibitors, process for preparing them and pharmaceutical compositions containing them | SANOFI AVENTIS (FR) | 2005-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | FGFR3, FGFR1, NTRK3 | KDM4E 3542/4885ALDH1A1 1784/4885THRB 646/4885 |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | KDM4E 3685/4885ALDH1A1 4185/4885THRB 572/4885 |
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | IDO2, IDO1, TPSB2 | KDM4E 1128/4885ALDH1A1 3074/4885THRB 3507/4885 |
| US-20130150413-A1 | BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CCR5, CCR2, CX3CR1 | KDM4E 4735/4885ALDH1A1 1360/4885THRB 1238/4885 |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | FGF2, FGF1, FGFR1 | KDM4E 2425/4885ALDH1A1 1502/4885THRB 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.